Pacific Edge (ASX:PEB) Common Stock: A$261.80 Mil (As of Mar. 2026)


ASX:PEB Pacific Edge Ltd ASX:PEB
46 GF Score
Price A$0.24
GF Value A$0.05
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Pacific Edge Common Stock?

Pacific Edge ASX:PEB -6.00% 46 Common Stock is A$261.80 Mil as of Mar. 2026. GuruFocus rates ASX:PEB with a GF Score™ of 46/100 and a GF Value™ of A$0.05 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Pacific Edge's quarterly common stock increased from Mar. 2025 (A$267.64 Mil) to Sep. 2025 (A$280.09 Mil) but then declined from Sep. 2025 (A$280.09 Mil) to Mar. 2026 (A$261.80 Mil).

Pacific Edge's annual common stock declined from Mar. 2024 (A$273.09 Mil) to Mar. 2025 (A$267.64 Mil) and declined from Mar. 2025 (A$267.64 Mil) to Mar. 2026 (A$261.80 Mil).

Pacific Edge Common Stock Historical Data

* Premium members only.

The historical data trend for Pacific Edge's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacific Edge Common Stock Chart

Pacific Edge Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 273.94 273.67 273.09 267.64 261.80

Pacific Edge Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 273.09 270.64 267.64 280.09 261.80
ASX:PEB
46GF Score
Pacific Edge Ltd ASX:PEB
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacific Edge Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of A$261.80 Mil mean?
Pacific Edge (ASX:PEB) has a Common Stock of A$261.80 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Pacific Edge and its competitors.
Is Pacific Edge's Common Stock too high?
Pacific Edge's current Common Stock is A$261.80 Mil. Overall, Pacific Edge has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's Common Stock compare to TMO and DHR?
Pacific Edge's Common Stock of A$261.80 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Medical Diagnostics & Research company?
A good Common Stock depends on the Medical Diagnostics & Research industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Pacific Edge and its competitors. Pacific Edge's current Common Stock is A$261.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.24 — trading 370% above its estimated fair value. The current Common Stock is A$261.80 Mil. Pacific Edge's overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current Common Stock is A$261.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Edge (ASX:PEB) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued. The current stock price of A$0.24 is trading 370% above its estimated GF Value™ of A$0.05. GuruFocus considers Pacific Edge to be Significantly Overvalued.

Key valuation signals for ASX:PEB:

  • Common Stock: A$261.80 Mil
  • GF Value™: A$0.05 vs. price of A$0.24 (370% above fair value)
  • GF Score™: 46/100 with 8 warning signs

No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacific Edge Business Description

Address 87 Saint David Street, P.O. Box 56, Dunedin, STL, NZL, 9016
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
46GF Score

Get the complete analysis for ASX:PEB

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.24
Price
A$0.05
GF Value